Shafiei S, Zaheriani M S, Sahfizad M, Ehteshami S, Mosazadeh M, Haddadi K. Neuroprotective Effects of Vitamin D on Patients With Traumatic Brain Injury: A Clinical Trial. Iran J Neurosurg 2022; 8 (1) : 4
URL:
http://irjns.org/article-1-291-en.html
1- Assistant Professor of Neurosurgery, Functional Fellowship, Department of Neurosurgery, Orthopedic Research Center, Mazandaran University of Medical Sciences, Sari, Iran
2- Resident of Neurosurgery, Department of Neurosurgery, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
3- Assistant Professor Neurosurgery, Functional Fellowship, Department of Neurosurgery, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
4- Assistant Professor Neurosurgery, Spine Fellowship, Department Of Neurosurgery, School Of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
5- MPH, PhD., in Epidemiology, Associate Professor, Gastrointestinal Cancer Research Center, Non-communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari,Ira
6- Associate Professor of Neurosurgery, Spine Fellowship, Department of Neurosurgery, Orthopedic Research Center, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran , kavehhaddadi56@gmail.com
Abstract: (2259 Views)
Background and Aim: Traumatic brain injury (TBI) is a globally-critical socioeconomic and public health problem. Introducing medications and strategies to treat and improve the prognosis of TBI is crucial. Current literature not only supports the key role of vitamin D on normal brain function, but also helps recovering from a myriad of pathologies. The present research was conducted to evaluate the neuroprotective effects of vitamin D on patients with TBI presenting to Imam Khomeini Hospital, Sari, Iran.
Methods and Materials/Patients: This randomized clinical trial assigned patients with vitamin D levels of over30 ng/ml to an intervention group (n=42) and a control group (n=42), who respectively received a single dose (150,000 units) of vitamin D and a placebo upon admission. The Glasgow Coma Score (GCS)
and mortality were recorded at the beginning of the study and three months after the final prescription.
Results: The mean GCS score upon admission was obtained as 8.64±2.29 in the vitamin D group and 8.42±2.93 in the placebo group. This score was respectively obtained as 13.50±1.85 and 10.97±2.37 upon discharge, suggesting a significant difference as per the t-test (P=0.04).The mean Glasgow Outcome Score (GOS) upon discharge was obtained as 4.24±1.51 in the intervention group and 4.10±1.40in the controls. The t-test suggested insignificant differences in the GOS between the two groups upon admission (P=0.823). After three months, the GOS respectively reaching desirable levels in 49.7% and 62.8% of cases in the placebo and intervention groups revealed statistically significant differences among the two groups (P=0.03).
Conclusion: The present results showed the improving effects of vitamin D on level of consciousness and outcomes in patients with acute TBI. More studies are suggested to be performed to investigate the effects of other medications, including amantadine and methylphenidate with a larger sample size.
Article number: 4
Full Text [PDF 1175 kb]
(736 Downloads)
| |
Full Text (HTML) (1161 Views)
• Given the profound biochemical effects of vitamin D on numerous pathways, this vitamin appeared useful in the acute phase of severe TBI.
• The present findings demonstrated the improving effect of vitamin D on level of consciousness in patients with acute TBI.
• Further studies with larger samples are required for clarifying the effects of other medications such as methylphenidate and amantadine.
Type of Study:
Clinical Trial |
Subject:
Neurotrauma